Which of the following statements comparing serotonin-dopamine antagonists (SDAs) with dopamine receptor antagonists (DRAs) is true?
DRAs is first choice of treatment for schizophrenia. SDAs produce more neurological adverse effects. SDAs produce more extrapyramidal symptoms. SDAs affect both serotonin and glutamate receptors.